Legislative Documents

Also, variously referred to as: House bills; House documents; House legislative documents; legislative documents; General Court documents

Additional file 8: of Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial

Figure S4. Comparison of individual raw data for alveolar volume (VA) and Vcap at different time points during experiment A and experiment B (N = 15). (DOCX 1406 kb

Additional file 2: of Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial

Table S2. Comparison of cardiorespiratory variables at rest and exercise between the two experimental conditions (N = 15). (DOCX 22 kb

Additional file 4: of Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial

Figure S1. Comparison of individual raw data for G’ (storage modulus) at 1 and 10 rad.s− 1 at different time points during experiment A and experiment B (N = 15). (DOCX 432 kb

TTV and HHV-7 viral loads did not correlate with symptoms.

<p>TTV virus loads in blood samples (A), TTV viral loads in throat swabs (B) and HHV-7 viral loads in throat swabs (C). HC: healthy controls, B: baseline (time of transplantation) of baseline enrollment patients, S: symptomatic visits of both enrollment scenarios, NS: non-symptomatic visits of both enrollment scenarios. Undetermined values were set to -2 log10 copies/μl for plotting and statistical analysis. Error bars show median and interquartile ranges, <i>p</i>-values are calculated with the Mann-Whitney U test.</p

Etiology of respiratory symptoms in lung transplant patients remained undetermined in almost half of analyzed episodes.

<p>A) Number of lung transplant patients enrolled at baseline and by indication (in total 71). Patients with baseline enrollment are grouped into those that never developed symptoms and those that developed at least one symptom (airway infection or dyspnea or decrease in FEV1) during the first 15 months after transplantation. B) Etiology of respiratory symptoms among 60 observed episodes as determined by routine diagnostic testing. Episodes for which all routine diagnostic tests were negative were summarized as unknown etiology.</p

Virus reads identified were distributed over the whole reference genomes.

<p>Coverage plots for respiratory viruses identified in patients gkc048, nrk011 (09/14), lpt371, rcn630, fyc360. The coverage calculated with <i>samtools depth</i> is shown at every position on the reference genome. The following reference genomes were used for alignment: Human rhinovirus B83 strain ATCC VR-1193 (FJ445161.1) for gkc048, Human rhinovirus A46 (DQ473506.1) for lpt371, Human rhinovirus A21 strain ATCC VR-1131 (FJ445121.1) for rcn630, Human rhinovirus A24 (EF173416.1) for nrk011 (09/14), Human coronavirus HKU1 strain N5P8 (DQ339101.1) for fyc360.</p

Virus reads reported by the bioinformatic pipeline.

<p>Virus reads reported by the bioinformatic pipeline.</p

Overview of visits of lung transplant cohort.

<p>Relative timeline of visits for patients of the indication enrollment (A) and for patients of the baseline enrollment starting at the transplantation (B). Symptoms are color coded as follows: no symptoms in green, airway infection in red, diarrhea in yellow, fever in blue, other symptoms (including dyspnea and decrease in FEV1) in purple, death of the patient in black.</p